|
1
|
Winkler F, Kozin SV, Tong RT, Chae SS,
Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E,
et al: Kinetics of vascular normalization by VEGFR2 blockade
governs brain tumor response to radiation: Role of oxygenation,
angiopoietin-1, and matrix metalloproteinases. Cancer Cell.
6:553–563. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lin MI and Sessa WC: Antiangiogenic
therapy: Creating a unique ‘window’ of opportunity. Cancer Cell.
6:529–531. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jain RK: Normalizing tumor vasculature
with anti-angiogenic therapy: A new paradigm for combination
therapy. Nat Med. 7:987–989. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Welén K, Jennbacken K, Tesan T and Damber
JE: Pericyte coverage decreases invasion of tumour cells into blood
vessels in prostate cancer xenografts. Prostate Cancer Prostatic
Dis. 12:41–46. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Faraone D, Aguzzi MS, Toietta G, Facchiano
AM, Facchiano F, Magenta A, Martelli F, Truffa S, Cesareo E,
Ribatti D, et al: Platelet-derived growth factor-receptor alpha
strongly inhibits melanoma growth in vitro and in vivo. Neoplasia.
11:732–742. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Manzur M and Ganss R: Regulator of G
protein signaling 5: A new player in vascular remodeling. Trends
Cardiovasc Med. 19:26–30. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Park SY, Kim YJ, Gao AC, Mohler JL, Onate
SA, Hidalgo AA, Ip C, Park EM, Yoon SY and Park YM: Hypoxia
increases androgen receptor activity in prostate cancer cells.
Cancer Res. 66:5121–5129. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yasuda H: Solid tumor physiology and
hypoxia-induced chemo/radio-resistance: Novel strategy for cancer
therapy: Nitric oxide donor as a therapeutic enhancer. Nitric
Oxide. 19:205–216. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bussink J, Kaanders JH and van der Kogel
AJ: Tumor hypoxia at the micro-regional level: Clinical relevance
and predictive value of exogenous and endogenous hypoxic cell
markers. Radiother Oncol. 67:3–15. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
O'Reilly MS, Boehm T, Shing Y, Fukai N,
Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR and Folkman J:
Endostatin: An endogenous inhibitor of angiogenesis and tumor
growth. Cell. 88:277–285. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rahman MA, Dhar DK, Yamaguchi E, Maruyama
S, Sato T, Hayashi H, Ono T, Yamanoi A, Kohno H and Nagasue N:
Coexpression of inducible nitric oxide synthase and COX-2 in
hepatocellular carcinoma and surrounding liver: Possible
involvement of COX-2 in the angiogenesis of hepatitis C
virus-positive cases. Clin Cancer Res. 7:1325–1332. 2001.PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shi Y, Sun Y, Yu J, Ding C, Wang Z, Wang
C, Wang D, Wang C, Wang Z, Wang M, et al: China experts consensus
on the diagnosis and treatment of advanced stage primary lung
cancer (2016 version). Asia Pac J Clin Oncol. 13:87–103. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li N, Zheng D, Wei X, Jin Z, Zhang C and
Li K: Effects of recombinant human endostatin and its synergy with
cisplatin on circulating endothelial cells and tumor vascular
normalization in A549 xenograft murine model. J Cancer Res Clin
Oncol. 138:1131–1144. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cui C, Mao L, Chi Z, Si L, Sheng X, Kong
Y, Li S, Lian B, Gu K, Tao M, et al: A phase II, randomized,
double-blind, placebo-controlled multicenter trial of Endostar in
patients with metastatic melanoma. Mol Ther. 21:1456–1463. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhu H, Yang X, Ding Y, Liu J, Lu J, Zhan
L, Qin Q, Zhang H, Chen X, Yang Y, et al: Recombinant human
endostatin enhances the radioresponse in esophageal squamous cell
carcinoma by normalizing tumor vasculature and reducing hypoxia.
Sci Rep. 5:145032015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Peng F, Xu Z, Wang J, Chen Y, Li Q, Zuo Y,
Chen J, Hu X, Zhou Q, Wang Y, et al: Recombinant human endostatin
normalizes tumor vasculature and enhances radiation response in
xenografted human nasopharyngeal carcinoma models. PLoS One.
7:e346462012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hamzah J, Jugold M, Kiessling F, Rigby P,
Manzur M, Marti HH, Rabie T, Kaden S, Gröne HJ, Hämmerling GJ, et
al: Vascular normalization in Rgs5-deficient tumours promotes
immune destruction. Nature. 453:410–414. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Silini A, Ghilardi C, Figini S, Sangalli
F, Fruscio R, Dahse R, Pedley RB, Giavazzi R and Bani M: Regulator
of G-protein signaling 5 (RGS5) protein: A novel marker of cancer
vasculature elicited and sustained by the tumor's proangiogenic
microenvironment. Cell Mol Life Sci. 69:1167–1178. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jin Y, An X, Ye Z, Cully B, Wu J and Li J:
RGS5, a hypoxia-inducible apoptotic stimulator in endothelial
cells. J Biol Chem. 284:23436–23443. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Turner KJ, Crew JP, Wykoff CC, Watson PH,
Poulsom R, Pastorek J, Ratcliffe PJ, Cranston D and Harris AL: The
hypoxia-inducible genes VEGF and CA9 are differentially regulated
in superficial vs invasive bladder cancer. Br J Cancer.
86:1276–1282. 2002. View Article : Google Scholar : PubMed/NCBI
|
